Compare Stocks: TNXP, CLYM, SLN, and ACRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$6.17 +3.7%	$5.77	$1.74 ▼ $6.60	$831.95M	0.79	1.59 million shs	1.75 million shs
CLYM Climb Bio	$15.52 +6.4%	$13.99	$1.54 ▼ $18.33	$837.99M	0.09	1.56 million shs	1.50 million shs
SLN Silence Therapeutics	$14.59 -1.4%	$11.97	$4.19 ▼ $17.58	$890.50M	1.45	1.95 million shs	463,590 shs
TNXP Tonix Pharmaceuticals	$13.14 -1.7%	$12.11	$9.40 ▼ $31.55	$229.31M	1.74	518,008 shs	252,185 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	-3.72%	-3.41%	-0.50%	+36.47%	+188.83%
CLYM Climb Bio	-3.06%	-3.12%	+16.16%	+38.29%	+497.95%
SLN Silence Therapeutics	0.00%	+9.96%	+32.41%	+139.71%	+195.21%
TNXP Tonix Pharmaceuticals	-0.07%	-1.40%	+19.27%	+20.78%	-51.73%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$6.17 +3.7%	$5.77	$1.74 ▼ $6.60	$831.95M	0.79	1.59 million shs	1.75 million shs
CLYM Climb Bio	$15.52 +6.4%	$13.99	$1.54 ▼ $18.33	$837.99M	0.09	1.56 million shs	1.50 million shs
SLN Silence Therapeutics	$14.59 -1.4%	$11.97	$4.19 ▼ $17.58	$890.50M	1.45	1.95 million shs	463,590 shs
TNXP Tonix Pharmaceuticals	$13.14 -1.7%	$12.11	$9.40 ▼ $31.55	$229.31M	1.74	518,008 shs	252,185 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	-3.72%	-3.41%	-0.50%	+36.47%	+188.83%
CLYM Climb Bio	-3.06%	-3.12%	+16.16%	+38.29%	+497.95%
SLN Silence Therapeutics	0.00%	+9.96%	+32.41%	+139.71%	+195.21%
TNXP Tonix Pharmaceuticals	-0.07%	-1.40%	+19.27%	+20.78%	-51.73%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$11.33	83.83% Upside
CLYM Climb Bio	2.94	Moderate Buy	$25.92	68.82% Upside
SLN Silence Therapeutics	2.83	Moderate Buy	$53.50	269.04% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$24.50	86.91% Upside

Current Analyst Ratings Breakdown

Latest TNXP, CLYM, SLN, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	CLYM Climb Bio	B Riley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/4/2026	CLYM Climb Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00 ➝ $30.00
9/3/2026	CLYM Climb Bio	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$40.00
9/3/2026	CLYM Climb Bio	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$21.00 ➝ $25.00
9/3/2026	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $32.00
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
8/24/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $24.00
8/19/2026	CLYM Climb Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
8/11/2026	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$25.00 ➝ $32.00
8/10/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$27.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	110.09	N/A	N/A	$0.89 per share	6.93
CLYM Climb Bio	N/A	N/A	N/A	N/A	$4.17 per share	N/A
SLN Silence Therapeutics	$560K	1,558.69	N/A	N/A	$0.64 per share	22.65
TNXP Tonix Pharmaceuticals	$13.11M	17.15	N/A	N/A	$12.96 per share	1.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/5/2026 (Estimated)
SLN Silence Therapeutics	-$88.61M	-$1.28	N/A	N/A	N/A	-8,943.86%	-106.94%	-47.99%	11/5/2026 (Estimated)
TNXP Tonix Pharmaceuticals	-$124.02M	-$12.94	N/A	N/A	N/A	-548.64%	-68.99%	-61.31%	11/9/2026 (Estimated)

Latest TNXP, CLYM, SLN, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	SLN Silence Therapeutics	-$0.1387	-$0.26	-$0.1213	-$0.27	$1.13 million	N/A
8/10/2026	Q2 2026	TNXP Tonix Pharmaceuticals	-$2.64	-$2.44	+$0.20	-$2.44	$7.72 million	$13.54 million
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
CLYM Climb Bio	N/A	31.45	31.45
SLN Silence Therapeutics	N/A	7.42	7.42
TNXP Tonix Pharmaceuticals	N/A	6.61	6.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
CLYM Climb Bio	69.76%
SLN Silence Therapeutics	98.73%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
CLYM Climb Bio	2.60%
SLN Silence Therapeutics	3.00%
TNXP Tonix Pharmaceuticals	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	139.82 million	133.11 million	Optionable
CLYM Climb Bio	9	57.44 million	55.94 million	N/A
SLN Silence Therapeutics	100	60.21 million	58.40 million	Not Optionable
TNXP Tonix Pharmaceuticals	50	17.15 million	16.81 million	Not Optionable

TNXP, CLYM, SLN, and ACRS Headlines

Recent News About These Companies

TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26

September 2 at 6:19 PM | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

September 2 at 8:14 AM | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

September 2 at 7:00 AM | globenewswire.com

Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Acquires 2,000 Shares

September 1 at 4:51 AM | insidertrades.com

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock

August 31, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street Zen

August 29, 2026 | americanbankingnews.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen

August 29, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Director Richard Bagger Acquires 1,000 Shares

August 25, 2026 | insidertrades.com

Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) Director Purchases $12,600.00 in Stock

August 24, 2026 | marketbeat.com

Tonix Pharma Names CEO Seth Lederman Interim CMO

August 18, 2026 | tipranks.com

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

August 18, 2026 | marketbeat.com

Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript

August 17, 2026 | fool.com

Tonix Pharmaceuticals Earnings Call Highlights Surging TONMYA Momentum

August 12, 2026 | theglobeandmail.com

Tonix Pharmaceuticals: Stronger-Than-Expected Tonmya Launch, Expanded Market Access, and Advancing Pipeline Underpin Buy Rating

August 11, 2026 | tipranks.com

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

August 10, 2026 | markets.businessinsider.com

Tonix outlines TNX-4800 Phase II with ~3,300 participants while scaling TONMYA to ~150 reps by September

August 10, 2026 | seekingalpha.com

Tonix Pharmaceuticals Holding C (TNXP) Q2 FY2026 earnings call transcript

August 10, 2026 | finance.yahoo.com

Penny Stocks: What Does Tonix Pharmaceuticals (NASDAQ:TNXP) Update Signal?

August 10, 2026 | kalkinemedia.comK

Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...

August 10, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Q2 Earnings Call Highlights

August 10, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results

August 10, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, CLYM, SLN, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$6.17 +0.22 (+3.70%)

As of 04:00 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Climb Bio NASDAQ:CLYM

$15.52 +0.93 (+6.37%)

As of 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Silence Therapeutics NASDAQ:SLN

$14.59 -0.20 (-1.35%)

As of 04:00 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Tonix Pharmaceuticals NASDAQ:TNXP

$13.14 -0.23 (-1.72%)

As of 04:00 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNXP, CLYM, SLN, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNXP, CLYM, SLN, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNXP, CLYM, SLN, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, CLYM, SLN, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Climb Bio NASDAQ:CLYM

Silence Therapeutics NASDAQ:SLN

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNXP, CLYM, SLN, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNXP, CLYM, SLN, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNXP, CLYM, SLN, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, CLYM, SLN, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Climb Bio NASDAQ:CLYM

Silence Therapeutics NASDAQ:SLN

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools